Incyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. 

CEO
William J. Meury
CEOWilliam J. Meury
Employees
2,844
Employees2,844
Headquarters
Wilmington, Delaware
HeadquartersWilmington, Delaware
Founded
1991
Founded1991
Employees
2,844
Employees2,844

INCY Key Statistics

Market cap
24.51B
Market cap24.51B
Price-Earnings ratio
15.23
Price-Earnings ratio15.23
Dividend yield
Dividend yield
Average volume
2.25M
Average volume2.25M
High today
$119.08
High today$119.08
Low today
$117.00
Low today$117.00
Open price
$119.08
Open price$119.08
Volume
406.75K
Volume406.75K
52 Week high
$132.60
52 Week high$132.60
52 Week low
$75.48
52 Week low$75.48

Stock Snapshot

The current Incyte(INCY) stock price is $118.74, with a market capitalization of 24.51B. The stock trades at a price-to-earnings (P/E) ratio of 15.23.

On 2026-08-04, Incyte(INCY) stock traded between a low of $117.00 and a high of $119.08. Shares are currently priced at $118.74, which is +1.5% above the low and -0.3% below the high.

The Incyte(INCY)'s current trading volume is 406.75K, compared to an average daily volume of 2.25M.

In the last year, Incyte(INCY) shares hit a 52-week high of $132.60 and a 52-week low of $75.48.

In the last year, Incyte(INCY) shares hit a 52-week high of $132.60 and a 52-week low of $75.48.

INCY News

Investing.com 1d
H.C. Wainwright reiterates Incyte stock rating on JAK inhibitor data - Investing.com

...

H.C. Wainwright reiterates Incyte stock rating on JAK inhibitor data - Investing.com
TipRanks 1d
Incyte price target raised to $155 from $131 at Leerink

Leerink analyst Andrew Berens raised the firm’s price target on Incyte (INCY) to $155 from $131 and keeps an Outperform rating on the shares. Unlock powerful i...

Simply Wall St 2d
The Bull Case For Incyte Could Change Following New EU Opzelura Atopic Dermatitis Approval

In late July 2026, the European Commission approved Incyte’s Opzelura (ruxolitinib) cream for adults with moderate atopic dermatitis whose disease is inadequate...

The Bull Case For Incyte Could Change Following New EU Opzelura Atopic Dermatitis Approval

Analyst ratings

53%

of 30 ratings
Buy
40%
Hold
53.3%
Sell
6.7%

More INCY News

Simply Wall St 5d
Incyte Wins European Approval For Opzelura In Adult Atopic Dermatitis

Incyte received European Commission approval for Opzelura (ruxolitinib) cream to treat moderate atopic dermatitis in adults. This is Opzelura's second indicati...

Incyte Wins European Approval For Opzelura In Adult Atopic Dermatitis
Nasdaq 7d
Incyte Q2 Revenue Jumps 38%, Raises FY26 Sales Guidance

(RTTNews) - Incyte Corp. (INCY) on Tuesday reported an increase in second-quarter earnings and revenue, driven by strong growth across its commercial portfolio....

Incyte Q2 Revenue Jumps 38%, Raises FY26 Sales Guidance

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.